Insulin resistance syndrome: A potent culprit in cardiovascular disease

Journal of the American Dietetic Association

Volumn 104, Issue 2, 2004, Pages 176-179

  Coulston, Ann M ^a,c   Peragallo Dittko, Virginia ^b  

^a Nutrition Department   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIETETICS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NOTE; OBESITY; PATIENT EDUCATION; PROPHYLAXIS;

EID: 0842310503     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2003.12.011     Document Type: Article

References (20)

1. American Diabetes Association Web site. Available at: http://www.diabetes.org . Accessed July 31:2003.
2. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults Findings from the third National Health and Nutrition Examination Survey . JAMA. 287:2002;356-359.
3. Position Statement on the Insulin Resistance Syndrome. Endocrine Practice. 9:2003;240-253.
4. Haffner S.M., Mykkanen L., Festa A., Burke J.P., Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects Implications for preventing coronary artery disease during the prediabetic state . Circulation. 101:2000;975-980.
5. Buchanan T.A., Xiang A.H., Kjos S.L., Trigo E., Lee W.P., Peters R.K. Antepartum predictors of the development of T2DM in Latino women 11-26 months after pregnancies complicated by gestational diabetes. Diabetes. 48:1999;2430-2436.
6. Cavaghan M.K., Ehrmann D.A., Polonsky K.S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 106:2000;329-336.
7. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 263:1990;2893-2898.
8. Reaven G.M. Banting lecture Role of insulin resistance in human disease . Diabetes. 37:1988;1595-1607.
9. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
10. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.-R. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689.
11. Taylor S.I. Lilly Lecture: Molecular mechanisms of insulin resistance: Lessons from patients with mutations in the insulin-receptor gene. Diabetes. 41:1992;1473-1490.
12. Haffner S.M., D'Agostino R., Saad M.F., Rewers M., Mykkanen L., Selby J., Howard G., Savage P.J., Hamman R.F., Wagenknecht L.E. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic Whites. The Insulin Resistance Atherosclerosis Study. Diabetes. 45:1996;742-748.
13. Kendall D.M., Sobel B.E., Coulston A.M., Harmel A.J.P., McLean B.K., Peragallo-Dittko V., Fonseca V.A., Hill J.O., Nesto R.W. The insulin resistance syndrome and coronary artery disease. Coronary Artery Disease. 14:2003;335-348.
14. Wilson P.W.F., Grundy S.M. The metabolic syndrome: A practical guide to origins and treatment: Part I. Circulation. 108:2003;1422-1425.
15. Reduction in the incidence of T2DM with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.
16. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., Keinanen-Kiukaanniemi S., Laasko M., Louheranta A., Rastas M., Salminen V., Uusitupa M. Prevention of T2DM mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344:2001;1343-1350.
17. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., Hu Z.X., Lin J., Xiao J.Z., Cao H.B., Lis P.A., Jiang X.G., Jiang Y.Y., Wang J.P., Zheng H., Zhang H., Bennett P.H., Howard B.V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance The DaQing IGT and Diabetes Study . Diabetes Care. 20:1997;537-544.
18. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458.
19. Wilson P.W.F., Grundy S.M. The metabolic syndrome: A practical guide to origins and treatment: part II. Circulation. 108:2003;1537-1540.
20. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of T2DM. Diabetes Care. 26:2003;2518-2523.